85.10
-2.71%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shanghai Allist Pharmaceuticals Co
Its shares trade on Shanghai under the ticker 688578.SS. It has been listed since 2 December 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥5.17bn and net income of CN¥2.18bn. At that date it held total assets of CN¥7.90bn and shareholders' equity of CN¥6.50bn.
Shanghai Allist Pharmaceuticals Co., Ltd. engages in the establishment of new drug research and development system. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-12-02. The firm has built a research and development pipeline in the field of small molecule targeted drugs for non-small cell lung cancer. The firm has established a complete new drug research and development system, covering all aspects of lead drug discovery and optimization, candidate drug evaluation and establishment, drug preclinical and clinical research, drug registration and application, industrialization and commercialization. The firm has a number of research pipeline projects under development, such as vometinib. Its drugs are used in the fields of blood pressure reduction, anti-tumor, anti-diabetic and gastric acid related diseases.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 2 Dec 2020
- Employees
- 870
- Website
- allist.com.cn ↗
Leadership
Pay as last reported
- Mr. Jinhao DuChairman of the Board, General Manager, since 2004CN¥1.9m
- Ms. Guilian ZengFinance Director, Chief Operating OfficerCN¥836,200
- Mr. Jie HuDeputy General Manager, Director, since 2019CN¥1.3m
- Mr. Hongxing GaoDeputy General ManagerCN¥1.5m
- Mr. Huibing LuoDeputy General ManagerCN¥1.7m
- Mr. Feng XuDeputy General ManagerCN¥1.3m
- Ms. Yong JiangDirector of Clinical RegistryCN¥687,000
- Ms. Huafeng ShanChief Quality OfficerCN¥696,200
- Mr. Hui ZhangProduction DirectorCN¥633,600
- Mr. Qiang ZhangProcess DirectorCN¥931,000
- Ms. Xiaofang ZhangIntellectual Property DirectorCN¥582,000
- Mr. Huayong ZhouDeputy Chief Research and Development Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shanghai Allist Pharmaceuticals has a strong R&D pipeline for small molecule targeted drugs in non-small cell lung cancer.
- The company employs 870 full-time employees focused on drug development and commercialization.
- Shanghai Allist Pharmaceuticals has established a complete new drug R&D system covering all development stages.
Weaknesses
- Shanghai Allist Pharmaceuticals has no mention of international market presence beyond China.
- The company's business is limited to specific therapeutic areas like anti-tumor and anti-diabetic drugs.
- Shanghai Allist Pharmaceuticals has no indication of partnerships with global pharmaceutical companies.
Opportunities
- Shanghai Allist Pharmaceuticals can expand its R&D pipeline into new therapeutic areas like cardiovascular diseases.
- The firm can leverage its existing R&D system to develop drugs for the growing global oncology market.
- Shanghai Allist Pharmaceuticals may benefit from increasing demand for targeted cancer therapies in China.
Threats
- Shanghai Allist Pharmaceuticals faces competition from established Chinese pharmaceutical firms in the oncology sector.
- The company's reliance on a single therapeutic area for its pipeline poses a risk if market demand shifts.
- Shanghai Allist Pharmaceuticals must navigate regulatory challenges in the Chinese pharmaceutical industry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.